Cannabis Law Report

JUNE 21, 2021

June 14, 2021 – June 18, 2021. OTC: EHVVF) adds Dr. Jeffrey Kamlet, an expert on cardiac safety in ibogaine treatment, as Chief Medical Officer. retains CRO Sante Cannabis to conduct clinical trials in psilocybin therapies. PsyIndex Weekly Update. ATAI Life Sciences N.V. Market Performance. (OTC:

Clinical Trials 66

Clinical Trials Research and Development Therapy Pharmaceutical 66

Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JULY 28, 2021

million fundraise and admission to the standard segment of the Official List and to trading on the London Stock Exchange Group plc’s Main Market for listed securities in May 2021 (together “Admission”). Publication of its final results for the year ended 31 May 2021 will be approximately one month later.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Presentations at ASN Kidney Week 2021, November 4-7, 2021.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

OCTOBER 20, 2021

NORML warns consumers to only obtain Delta-8 products from state-regulated cannabis manufacturers. s NORML Coordinator Dale Gieringer, Delta-8 has undergone minimal testing in humans, “therefore, little is known about its long-term safety, its consumption at high dosages, or its medicinal effects.” According to Calif.’s Law 360 (sub.

Hemp 52

Hemp Clinical Trials CBD Legalization 52

Cannabis Law Report

AUGUST 23, 2021

& Notice of 2021 Final Results. . At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials. Oxford Cannabinoid Technologies Holdings plc.

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

NOVEMBER 26, 2021

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2021. On September 30, 2021, Can-Fite had approximately $13.3 Fortified Balance Sheet.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Cannabis Law Report

DECEMBER 7, 2021

Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article. Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Stolar & Ilan Matok.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 52

Epilepsy Clinical Trials Research and Development Pharmaceutical 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.)

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The primary endpoint of this Phase 1 trial was safety and tolerability. During the six months ended September 30, 2021, the Company raised approximately $4.1

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

SEPTEMBER 22, 2021

Pnina Fishman will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021 and will join a panel discussion regarding medical cannabis. Details are below: Medical Cannabis Panel. Date: Wednesday, September 29, 2021. Date: Wednesday, September 29, 2021. Time: 11:55 am – 12:35 pm ET.

Clinical Trials 52

Clinical Trials Treatment Business Events 52

Cannabis Law Report

OCTOBER 22, 2021

The “Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” report provides comprehensive insights for about 25+ companies and 50+ pipeline drugs in Medical Marijuana – Cannabidiol pipeline landscape.

Research and Development 52

Research and Development Pharmaceutical Marijuana Chronic Pain 52

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinical trials examining the efficacy of cannabinoids for ASD? 17 Aug 2021. Fletcher S. Child: care, health and development.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

Canna Law Blog

NOVEMBER 6, 2021

To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

NOVEMBER 19, 2021

19, 2021 /CNW/ – PsyBio Therapeutics Corp. “These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

NOVEMBER 1, 2021

CBD Rich T3/C15 cannabis fraction works via the A3AR target to inhibit the growth of HEP-3b hepatocellular carcinoma cells. The findings have been published in an abstract in the October 2021 supplement of HEPATOLOGY , a premier peer-reviewed publication in the field of liver disease published on behalf of the AASLD.

Clinical Trials 52

Clinical Trials Research and Development Treatment Business 52

Cannabis Law Report

AUGUST 5, 2021

Although the overarching market is still relatively new, much like the cannabis boom a few years ago the psychedelics space is growing at an unprecedented rate. Thanks to the license, Filament will look to create the first-ever natural pharmaceutical grade extracts and put them into clinical trials in order to demonstrate safety and efficacy.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. NEW YORK , June 4, 2021 /PRNewswire/ — AIkido Pharma Inc. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

JULY 8, 2021

Enveric Enters into Clinical Stage Development of Lead Asset, EV101, in Israel with MOH Approval. We are targeting the fourth quarter of 2021 for the enrollment of our first patient, following the conclusion of the final study agreements with the site.” ” This product is not approved for marketing anywhere in the world.

Treatment 98

Treatment Clinical Trials CBD Patients 98

Cannabis Law Report

AUGUST 3, 2021

The Shares were offered in each of the provinces of Canada, excluding Québec, pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

The Cannigma

MARCH 7, 2022

Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . Of course, this plant is now known to be marijuana (or Type I cannabis), which is still commonly used for sleep and analgesia today. The best online schools for medical cannabis training.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Canna Law Blog

NOVEMBER 15, 2021

Some of these companies are already engaged in clinical trials , a key indicator that significant capital and resources are behind entrants into the market. Coupled with the fact that , as of October 2021, 50 psychedelics companies are now publicly listed on U.S. Psychedelics are not cannabis.

Clinical Trials 98

Clinical Trials Treatment Microdosing Pharmaceutical 98

Cannabis Law Report

AUGUST 22, 2021

16, 2021 /CNW/ — PsyBio Therapeutics Corp. PsyBio intends to continue utilizing its resources to rapidly develop and test new drug candidates within this and other psychedelic categories in anticipation of launching future clinical trials. OXFORD, Ohio and COCONUT CREEK, Fla., ” About PsyBio Therapeutics Corp. .

Clinical Trials 98

Clinical Trials Research and Development Treatment Conditions 98

Cannabis Law Report

JUNE 25, 2021

DUBLIN–(BUSINESS WIRE)–The “Skin Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030” report has been added to ResearchAndMarkets.com’s offering. billion in 2021 at a compound annual growth rate (CAGR) of 11.8%. Cannabis Science Inc. billion in 2020 to $1.61 Pfizer Inc.

Research and Development 84

Research and Development Therapy Pharmaceutical Clinical Trials 84

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. MAPS Public Benefit Corporation will coordinate trial design with Medicines and Healthcare products Regulatory Agency to create a road map for early patient access in the UK.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

OCTOBER 18, 2021

DUBLIN–(BUSINESS WIRE)–The “Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. 9-THC, the primary psychoactive component of cannabis. Cannabis oil: TO Pharmaceuticals. BX-1: Bionorica SE. Key Questions Answered.

Research and Development 52

Research and Development Pharmaceutical Chronic Pain Therapy 52

Cannabis Law Report

DECEMBER 26, 2021

December 17, 2021 ·. – December 16, 2021) – Entheon Biomedical Corp. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. Further to the Corporate Update provided on November 24, 2021, the Company is pleased to announce further progress on its nonclinical program.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

JUNE 7, 2021

Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others. Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final or conditional approval from the U.S. Follow us on Twitter and LinkedIn.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

JULY 9, 2021

In June 2021, similar measures were passed in Connecticut and Texas, where medical research on psilocybin is now also legal on a statewide level. Joyce Cutler, Texas the Latest State to Legalize Psychedelic Medical Research, BLOOMBERG LAW (June 23, 2021), available at [link]. March 8, 2021). Id ; 21 CFR 312.1-10;

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

JULY 7, 2021

We remain encouraged as we continue our evaluations of MYMD-1 for efficacy and safety – especially as studies continue to suggest we may be able to address many of the concerns that are associated with the current drugs on the market today in these disease areas.”. President, Director and Chief Medical Officer of MyMD. “We

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105